====== Michael Kent Ranson ======

{{ ::michael-kent-ranson_source.jpeg?200|}}

**Michael Kent Ranson** is a Canadian health economist. He is notable in the [[COVID-19 pandemic]] due to his role as a board member for [[gavi|Gavi, the Vaccine Alliance]].

===== Background =====

==== Education ====

Ranson holds an MD from [[McMaster University]], an MPH from the [[Harvard School of Public Health]], and a DPhil in health economics and financing from the [[London School of Hygiene and Tropical Medicine]].((//Michael Kent Ranson.// (2021, October 22). Gavi, the Vaccine Alliance. http://archive.today/2022.07.25-215508/https://www.gavi.org/governance/gavi-board/members/michael-kent-ranson))

===== Career =====

==== London School of Hygiene and Tropical Medicine ====

Ranson researched, wrote and taught on health financing and system issues, first as a lecturer at the London School of Hygiene and Tropical Medicine (LSHTM), where he led a cluster randomised trial aimed at improving the equity impact of a community-based insurance program in [[india:Gujarat]], [[India]]. 

==== World Health Organization ====

Later, at the [[World Health Organization]], he supported health policy and systems research and led the secretariat for the First and Second [[Global Symposium on Health Systems Research]] under [[Health Systems Global]].((Milko, E., Wu, D., Neves, J., Neubecker, A. W., Lavis, J., & Ranson, M. K. (2014). //Second Global Symposium on Health Systems Research: a conference impact evaluation.// Health Policy and Planning, 30(5), 612–623. https://doi.org/10.1093/heapol/czu040))

==== World Bank ====

Ranson has been a Senior Health Economist based in the [[World Bank]] office in [[switzerland:Geneva]] since 2014. He is the World Bank’s focal point for engagement with [[Gavi]] and [[COVAX]], and has served as Gavi Board Alternate and on the Gavi Programme and Policy Committee since 2018. 

He is part of the team that developed a new mechanism that allows countries to use World Bank financing to purchase [[COVID-19 vaccines]], beyond the fully donor-subsidized doses they are already receiving, through COVAX. He is co-chair of the [[Immunization Agenda 2030]] Financial Sustainability working group.

He also participated on the [[UHC2030]] Working Group on Sustainability, Transition from Aid and Health System Strengthening in 2017.((//First face to face meeting of the UHC2030 Working Group on Sustainability, Transition from Aid and Health System Strengthening.// (2017, March). UHC2030. https://web.archive.org/web/20210623044309/https://www.uhc2030.org/fileadmin/uploads/uhc2030/Documents/About_UHC2030/UHC2030_Working_Groups/2017_Transition_working_group_docs/Provisional_lst_of_participants_30-31_March_2017__1_.pdf))

===== Other affiliations =====

  * [[Alliance for Health Policy and Systems Research]]
  * [[Centre for Health Economics and Policy Analysis]]
  * [[Harvard University]], Department of Health and Policy Management
  * [[Health Economics and Systems Analysis Group]] (HESA)
  * [[London School of Economics and Political Science]]
  * [[McMaster Health Forum]]
  * [[Michael DeGroote School of Medicine]], [[McMaster University]]
  * [[Program in Policy Decision-Making]]
  * [[Public Health Foundation of India]]
  * [[Queen's University]]
  * [[Royal Holloway, University of London]]
  * [[University of British Columbia]]
  * [[University of Cape Town]]
  * [[University of Geneva]]
  * [[University of Toronto]]